Therapeutic Transformation for Patients with Diabetes and CKD
Publication Title
RPA Annual Meeting
Document Type
Presentation
Publication Date
3-20-2021
Keywords
washington; spokane
Abstract
SGLT2 inhibitors represent a major advance in the treatment of patients with chronic kidney disease due to their ability to slow progression of CKD and delay the need for dialysis. They also have been shown to have cardio-protective effects.
Area of Special Interest
Kidney & Diabetes
Specialty/Research Institute
Nephrology
